INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.320
-0.010 (-0.75%)
At close: Mar 9, 2026, 4:00 PM EDT
1.310
-0.010 (-0.76%)
After-hours: Mar 9, 2026, 4:10 PM EDT
INmune Bio Employees
As of December 31, 2024, INmune Bio had 22 total employees, including 13 full-time and 9 part-time employees. The number of employees increased by 5 or 29.41% compared to the previous year.
Employees
22
Change (1Y)
5
Growth (1Y)
29.41%
Revenue / Employee
$2,273
Profits / Employee
-$2,267,591
Market Cap
35.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Atara Biotherapeutics | 38 |
| Lisata Therapeutics | 26 |
| Actinium Pharmaceuticals | 25 |
| PDS Biotechnology | 24 |
| ABVC BioPharma | 19 |
| Outlook Therapeutics | 17 |
INMB News
- 10 days ago - INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript - Seeking Alpha
- 10 days ago - INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript - Seeking Alpha
- 14 days ago - INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar - GlobeNewsWire
- 18 days ago - INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - GlobeNewsWire
- 27 days ago - INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - GlobeNewsWire
- 5 weeks ago - INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - GlobeNewsWire
- 3 months ago - Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform - GlobeNewsWire
- 3 months ago - INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients - GlobeNewsWire